Go To Main TNBC Website


  New Posts New Posts RSS Feed - Study of Temsirolimus, Erlotinib and Cisplatin in
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Study of Temsirolimus, Erlotinib and Cisplatin in

 Post Reply Post Reply
Author
Terje View Drop Down
Senior Member
Senior Member
Avatar

Joined: Nov 07 2009
Location: San Jose
Status: Offline
Points: 215
Post Options Post Options   Thanks (0) Thanks(0)   Quote Terje Quote  Post ReplyReply Direct Link To This Post Topic: Study of Temsirolimus, Erlotinib and Cisplatin in
    Posted: Feb 19 2010 at 1:53pm
Does anyone know anything about this?


Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
http://www.clinicaltrials.gov/ct2/show/NCT00998036
Quote Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Phase: Phase I



http://en.wikipedia.org/wiki/Temsirolimus
Quote Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007,[1] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.



http://en.wikipedia.org/wiki/Erlotinib
Quote Erlotinib hydrochloride (Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche.
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 11.05
Copyright ©2001-2016 Web Wiz Ltd.